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Background
Carbon monoxide (CO) is a signaling molecule that con-
trols many physiological processes in mammalian tissues.
CO gas activates sGC by 3–4-fold and exerts vasodilatory
effects through elevation of cGMP. Certain transition
metal carbonyls liberate CO in a controlled fashion and
function as CO-releasing molecules (CORMs). Some of
these agents have a variety of pharmacological effects and
have yielded encouraging results in preclinical models,
where CORM administration alleviates inflammatory
processes and cardiovascular disorders. The aim of the
present work was to investigate whether the pharmacolog-
ical effects of CORMs could be attributed to sGC activa-
tion. To this end, we selected 12 CORMs and tested their
ability to alter cGMP levels.
Materials and methods
Rat aortic smooth muscle cells (RASMC) were incubated
with IBMX (1 mM) for 5 min. Cells were then treated with
vehicle, sodium nitroprusside (SNP) 10 μÌ, CO and/or
CORMs at various concentrations (1–100 μÌ) for 15 min;
cGMP was extracted and measured by enzyme immu-
noassay. To establish co-cultures we seeded endothelial
cells on confluent RASMCs; co-cultures were then treated
a CORMs, in the presence or absence of bradykinin (10
μÌ). Basal and DEA-NO (1 μÌ)-stimulated guanylyl cyclase
activity was also measured in the presence of CORMs (10
and 100 μÌ).
Results
CO and 4 of the CORMs (ALF 153, 157, 436 and CORM-
2) increased cGMP levels in smooth muscle cells, while
the rest of the compounds failed to alter cGMP produc-
tion. The CORM-stimulated increase was minor (50–
300% over basal) compared to the effects seen with the
NO-donor, SNP (at least 100-fold). CORM-3, a widely
used CORM, decreased basal cGMP levels in RASMC.
Interestingly, CO and CORMs modestly reduced SNP-
stimulated cGMP formation in RASMC. The inactive
forms of CORMs (compounds lacking the ability to liber-
ate CO) did not affect SNP-induced cGMP accumulation.
CORMs also reduced bradykinin-stimulated cGMP levels
in endothelial-smooth muscle co-cultures. In sGC activity
assays using purified recombinant human sGC, CORMs
were ineffective in stimulating cGMP production. How-
ever, CORMs blocked up to 80% of DEA-NO-induced
sGC activity.
Conclusion
Collectively, our findings suggest that CORMs, due to
their different chemical nature and physico-chemical
properties may have complex and indirect effects on the
NO/cGMP pathway, resulting in either stimulation or
inhibition of intracellular cGMP levels.
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